home / stock / mtem / mtem news

MTEM News and Press, Molecular Templates Inc. From 03/28/24

Stock Information
Company Name: Molecular Templates Inc.
Stock Symbol: MTEM
Market: NASDAQ
Website: mtem.com
Menu
MTEM MTEM Quote MTEM Short MTEM News MTEM Articles MTEM Message Board
Get MTEM Alerts

News, Short Squeeze, Breakout and More Instantly...
MTEM - Molecular Templates announces $9.5M private placement offering

2024-03-28 09:04:08 ET More on Molecular Templates Seeking Alpha’s Quant Rating on Molecular Templates Historical earnings data for Molecular Templates Financial information for Molecular Templates Read the full article on Seeking Alpha For fur...
MTEM - Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known a...

MTEM - Molecular Templates Inc. (NASDAQ: MTEM) Leading the Way in Monday Trading Based on Percentage Gain

Molecular Templates, Inc. (NASDAQ: MTEM) is one of today's top gainers. The company's shares have moved 25.97% on the day to $2.33. Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of canc...

MTEM - Molecular Templates, Inc. Provides Interim Update

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, enginee...
MTEM - Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, ...

MTEM - Molecular Templates GAAP EPS of -$0.82 beats by $1.13, revenue of $6.8M beats by $4.34M

2023-11-13 17:48:58 ET More on Molecular Templates Seeking Alpha’s Quant Rating on Molecular Templates Historical earnings data for Molecular Templates Financial information for Molecular Templates For further details see: Molecular Templates GAAP ...

MTEM - Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineer...
MTEM - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

MTEM - Expected earnings - Molecular Templates Inc.

Molecular Templates Inc. (MTEM) is expected to report $-2.7 for Q3 2023

MTEM - Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today ann...
Previous 10 Next 10